Astral drops unified-brand strategy, CPVC plant on track for Q1 FY27
Management reverses earlier stance, now says 'Astral Chemi' must stand alone. Paints to turn EBITDA positive this fiscal, UK adhesives to double EBITDA from ₹15 cr baseline.
— 3 earlier stories on Astral Ltd. →What's new
- CPVC resin plant on track for Q1 FY27 commercial production; trial runs of 3,000-5,000 tons in Q4.
- Management reverses unified-brand strategy, now argues Astral Chemi must be perceived as independent.
- Paints division targets EBITDA positive in current fiscal; UK adhesives EBITDA to more than double from ₹15 cr.
Why this matters
The branding reversal is a notable shift — management had earlier pushed for a single brand but now sees the chemicals business needs its own identity. The concrete guidance on paints turning profitable and adhesives scaling cements the demerger narrative, but the lack of a post-demerger dividend policy leaves a key investor question unanswered.
What we're watching
- Can Astral Chemi establish independent brand equity post-demerger?
- Execution on CPVC resin ramp-up and the 200 bps margin improvement it promises.
- DSS Specialty Chemicals' path to ₹150 cr revenue with 20-25% EBITDA margins.
The full read
Astral's latest concall locked in concrete numbers for its demerger units. The reversal is stark. Management reversed its earlier unified-brand strategy, now saying Astral Chemi must stand alone to be credible. On operations, the CPVC resin plant is on track for Q1 FY27, with trial runs of 3,000-5,000 tons in Q4. Paints should turn EBITDA positive this fiscal. UK adhesives EBITDA is set to more than double from ₹15 crore. DSS Specialty Chemicals targets ₹150 crore revenue at 20-25% EBITDA margins, with a five-year vision of ₹500 crore. Capex cycles are largely done; routine spend will be ₹14-15 crore a year. The open question is the dividend policy. Management deferred, adding uncertainty for income investors. The market had heard much of this live, but the concall now provides the specificity that was previously ambiguous.
Questions answered
- Why did Astral reverse its unified-brand strategy?
- Management said 'Astral Chemi' must emerge from the pipe business's shadow to be seen as an independent entity, justifying the demerger.
- What is the timeline for the CPVC resin plant?
- Commercial production expected in Q1 FY27, with trial runs of 3,000-5,000 tons in the current Q4.
- When will the paints division turn EBITDA positive?
- Management expects paints to be EBITDA positive in the current fiscal year.
- What are the targets for UK adhesives?
- EBITDA is projected to more than double from the ₹15 crore baseline.
- What are the revenue targets for DSS Specialty Chemicals?
- Targeting ₹150 crore revenue at 20-25% EBITDA margins this year, with a five-year vision of ₹500 crore.
- Will there be a dividend policy post-demerger?
- The board will decide approximately nine months after scheme closure; management declined to specify a policy yet.
Astral Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ASTRAL →- 28 Jun 2026 · 3:51 PM IST Astral drops unified-brand strategy, CPVC plant on track for Q1 FY27
- today Astral reviews demerger scheme 10 days after board approval
- 30d ago Astral's PEX pipe launch slips to September, CPVC plant to Q4 FY27
- 32d ago Astral lines up 51 institutional desks for June 8 meet